Overcoming Drug Development Obstacles for Some of the Most Challenging Ischemic Conditions

Key Takeaways

• Recombinant KLK1 targets bradykinin B2 receptors in ischemic tissue
• Phase‑2 data show maternal BP drop, no fetal drug exposure
• Stroke market lacks new drugs since tPA approval in 1996
• Over 300 patients dosed across DiaMedica’s ischemia programs
• Improved uterine artery Doppler indices suggest better placental perfusion

Summary

DiaMedica Therapeutics is advancing a recombinant tissue kallikrein (KLK1) to treat ischemic stroke and preeclampsia, leveraging the kallikrein‑kinin pathway to restore microvascular flow. Early trials show maternal blood‑pressure reductions, improved uterine‑artery Doppler indices, and no detectable drug in fetal circulation, addressing safety concerns. The program builds on extensive experience with urinary kallikrein in China and Japan, where similar proteins treat millions annually. By targeting diseases with few approved therapies, DiaMedica aims to fill a major unmet medical need in both neurology and obstetrics.

Pulse Analysis

The ischemic cascade that underlies acute stroke and placental insufficiency remains a stubborn therapeutic frontier. DiaMedica’s recombinant tissue kallikrein (KLK1) seeks to exploit the kallikrein‑kinin system, delivering bradykinin directly to the penumbra where B2 receptors are dramatically up‑regulated. By generating localized vasodilation, the drug aims to restore microvascular flow without systemic hypotension. This biologic approach contrasts with the clot‑focused paradigm of tissue plasminogen activator, the only stroke drug approved since 1996, and could broaden treatment windows for patients who miss thrombolysis or thrombectomy.

In preeclampsia, the dual‑maternal‑fetal safety profile is the primary barrier to drug development. DiaMedica’s 26‑kilodalton KLK1 protein sits well above the ~500‑dalton placental cutoff, a fact confirmed in a phase‑2 study that detected the molecule in maternal plasma but not in cord blood. The trial also reported consistent reductions in systolic blood pressure and a measurable decline in uterine artery pulsatility index, indicating improved placental perfusion. By acting as a protein replacement for the naturally deficient kallikrein in affected women, the therapy promises to extend gestation and reduce neonatal intensive‑care stays.

The commercial upside of a first‑in‑class ischemic vasodilator is sizable. With over 300 patients already dosed and a clear regulatory path that emphasizes maternal safety, DiaMedica positions itself as a rare contender in a pipeline dominated by oncology and metabolic agents. Success could catalyze further investment in the kallikrein‑kinin pathway, encouraging competitors to explore similar protein‑based solutions for other blood‑flow‑limited conditions. For health systems, even modest extensions of pregnancy or reductions in stroke disability translate into lower long‑term costs and improved quality of life.